Startups sell off-label longevity drugs without clinical data
Biotech firms are now marketing rapamycin and metformin for anti-aging directly to consumers despite a total lack of long-term clinical trial data for healthy adults. This examines the regulatory loophole allowing 'off-label' prescriptions to become a billion-dollar wellness industry.
Listen in the Fylom app.
Twenty-one percent of all United States prescriptions are now written for off-label uses.
Rapamycin has extended the lifespan of mice by ten to twenty-five percent in laboratory studies.
Metformin can reduce mitochondrial adaptations to aerobic exercise by thirty to fifty percent.
Telehealth startups are bypassing decade-long clinical trials to sell unapproved aging protocols directly to consumers.
The longevity market is projected to reach a ten billion dollar valuation by twenty twenty-six.
Companies are using epigenetic clocks as biological biomarkers to bridge the gap in slow clinical data.
- 01Intro1 min
- 02The Rise of the Longevity Telehealth Loophole2 min
- 03Rapamycin: From Organ Transplants to the Fountain of Youth3 min
- 04Metformin and the TAME Trial Standoff3 min
- 05The Regulatory Future: One Trial vs. Two2 min
- 06Outro1 min
Fylom generates episodes like this on any topic you're curious about.
Fylom episodes are researched, written, and voiced by AI. Automated checks help catch inaccuracies, but episodes aren't reviewed by a human and AI can still get things wrong. Treat them as a starting point, not a source of record — more in our accuracy disclaimer.